Switch theme
Sign up to access all valuation multiples
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. The only reportable segment of the company is the Pharmaceuticals business segment, which engages mainly in the research and development, manufacturing and sales of pharmaceutical products. It has a geographic presence in the United States, Malta, Taiwan, and Others.
1966
750
LTM Revenue $644M
LTM EBITDA $275M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lotus Pharmaceutical has a last 12-month revenue (LTM) of $644M and a last 12-month EBITDA of $275M.
In the most recent fiscal year, Lotus Pharmaceutical achieved revenue of $620M and an EBITDA of $274M.
Lotus Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lotus Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $644M | XXX | $620M | XXX | XXX | XXX |
| Gross Profit | $385M | XXX | $364M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $275M | XXX | $274M | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 44% | XXX | XXX | XXX |
| EBIT | $216M | XXX | $201M | XXX | XXX | XXX |
| EBIT Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $177M | XXX | $169M | XXX | XXX | XXX |
| Net Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $245M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lotus Pharmaceutical's stock price is TWD 235 (or $8).
Lotus Pharmaceutical has current market cap of TWD 61.5B (or $2.1B), and EV of TWD 68.3B (or $2.3B).
See Lotus Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.1B | XXX | XXX | XXX | XXX | $0.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lotus Pharmaceutical has market cap of $2.1B and EV of $2.3B.
Lotus Pharmaceutical's trades at 3.7x EV/Revenue multiple, and 8.3x EV/EBITDA.
Equity research analysts estimate Lotus Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lotus Pharmaceutical has a P/E ratio of 11.6x.
See valuation multiples for Lotus Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | 8.3x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBIT | 10.6x | XXX | 11.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.6x | XXX | 12.1x | XXX | XXX | XXX |
| EV/FCF | 11.9x | XXX | 14.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLotus Pharmaceutical's last 12 month revenue growth is 8%
Lotus Pharmaceutical's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.2M for the same period.
Lotus Pharmaceutical's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lotus Pharmaceutical's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lotus Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 44% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | 48% | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lotus Pharmaceutical acquired XXX companies to date.
Last acquisition by Lotus Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Lotus Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lotus Pharmaceutical founded? | Lotus Pharmaceutical was founded in 1966. |
| Where is Lotus Pharmaceutical headquartered? | Lotus Pharmaceutical is headquartered in Taiwan. |
| How many employees does Lotus Pharmaceutical have? | As of today, Lotus Pharmaceutical has 750 employees. |
| Who is the CEO of Lotus Pharmaceutical? | Lotus Pharmaceutical's CEO is Mr. Petar Antonov Vazharov. |
| Is Lotus Pharmaceutical publicy listed? | Yes, Lotus Pharmaceutical is a public company listed on TAI. |
| What is the stock symbol of Lotus Pharmaceutical? | Lotus Pharmaceutical trades under 1795 ticker. |
| When did Lotus Pharmaceutical go public? | Lotus Pharmaceutical went public in 2010. |
| Who are competitors of Lotus Pharmaceutical? | Similar companies to Lotus Pharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Lotus Pharmaceutical? | Lotus Pharmaceutical's current market cap is $2.1B |
| What is the current revenue of Lotus Pharmaceutical? | Lotus Pharmaceutical's last 12 months revenue is $644M. |
| What is the current revenue growth of Lotus Pharmaceutical? | Lotus Pharmaceutical revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Lotus Pharmaceutical? | Current revenue multiple of Lotus Pharmaceutical is 3.5x. |
| Is Lotus Pharmaceutical profitable? | Yes, Lotus Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lotus Pharmaceutical? | Lotus Pharmaceutical's last 12 months EBITDA is $275M. |
| What is Lotus Pharmaceutical's EBITDA margin? | Lotus Pharmaceutical's last 12 months EBITDA margin is 43%. |
| What is the current EV/EBITDA multiple of Lotus Pharmaceutical? | Current EBITDA multiple of Lotus Pharmaceutical is 8.3x. |
| What is the current FCF of Lotus Pharmaceutical? | Lotus Pharmaceutical's last 12 months FCF is $191M. |
| What is Lotus Pharmaceutical's FCF margin? | Lotus Pharmaceutical's last 12 months FCF margin is 30%. |
| What is the current EV/FCF multiple of Lotus Pharmaceutical? | Current FCF multiple of Lotus Pharmaceutical is 11.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
